There is reason to believe that diabetic neuropathy may be related to the accumulation of sorbitol in nerve tissue through an aldose reductase pathway from glucose. Short-term treatment with aldose reductase inhibitors improves nerve conduction in subjects with diabetes, but the effects of long-term treatment on the neuropathologic changes of diabetic neuropathy are unknown. To determine whether more prolonged aldose reductase inhibition reverses the underlying lesions that accompany symptomatic diabetic peripheral polyneuropathy, we performed a randomized, placebo-controlled, double-blind trial of the investigational aldose reductase inhibitor sorbinil (250 mg per day). Sural-nerve biopsy specimens obtained at base line and after one year from 16 diabetic patients with neuropathy were analyzed morphometrically in detail and compared with selected electrophysiologic and clinical indexes. In contrast to patients who received placebo, the 10 sorbinil-treated patients had a decrease of 41.8 +/- 8.0 percent in nerve sorbitol content (P less than 0.01) and a 3.8-fold increase in the percentage of regenerating myelinated nerve fibers (P less than 0.001), reflected by a 33 percent increase in the number of myelinated fibers per unit of cross-sectional area of nerve (P = 0.04). They also had quantitative improvement in terms of the degree of paranodal demyelination, segmental demyelination, and myelin wrinkling. The increase in the number of fibers was accompanied by electrophysiologic and clinical evidence of improved nerve function. We conclude that sorbinil, as a metabolic intervention targeted against a specific biochemical consequence of hyperglycemia, can improve the neuropathologic lesions of diabetic neuropathy.
Source Information
Department of Pathology, University of Manitoba, Winnipeg, Canada.
This article has been cited by other articles:
Karamoysoyli, E., Burnand, R. C., Tomlinson, D. R., Gardiner, N. J.
(2008). Neuritin Mediates Nerve Growth Factor Induced Axonal Regeneration and Is Deficient in Experimental Diabetic Neuropathy. Diabetes
57: 181-189
[Abstract][Full Text]
Misawa, S., Kuwabara, S., Kanai, K., Tamura, N., Nakata, M., Sawai, S., Yagui, K., Hattori, T.
(2006). Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics. Neurology
66: 1545-1549
[Abstract][Full Text]
Sima, A. A.F., Calvani, M., Mehra, M., Amato, A., for the Acetyl-l-Carnitine Study Group,
(2005). Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care
28: 89-94
[Abstract][Full Text]
Bril, V., Ono, Y., Buchanan, R. A.
(2004). Sural Nerve Sorbitol in Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care
27: 1160-1163
[Abstract][Full Text]
Malik, R.
(2003). Failure to define the pathogenesis and treatment of human diabetic neuropathy. British Journal of Diabetes & Vascular Disease
3: 107-111
[Abstract]
Ekberg, K., Brismar, T., Johansson, B.-L., Jonsson, B., Lindstrom, P., Wahren, J.
(2003). Amelioration of Sensory Nerve Dysfunction by C-Peptide in Patients With Type 1 Diabetes. Diabetes
52: 536-541
[Abstract][Full Text]
Hotta, N., Toyota, T., Matsuoka, K., Shigeta, Y., Kikkawa, R., Kaneko, T., Takahashi, A., Sugimura, K., Koike, Y., Ishii, J., Sakamoto, N.
(2001). Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care
24: 1776-1782
[Abstract][Full Text]
Perkins, B. A., Olaleye, D., Zinman, B., Bril, V.
(2001). Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic. Diabetes Care
24: 250-256
[Abstract][Full Text]
Kennedy, J. M., Zochodne, D. W.
(2000). The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms. Brain
123: 2118-2129
[Abstract][Full Text]
Greene, D. A., Arezzo, J. C., Brown, M. B.
(1999). Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology
53: 580-580
[Abstract][Full Text]
Yabe-Nishimura, C.
(1998). Aldose Reductase in Glucose Toxicity: A Potential Target for the Prevention of Diabetic Complications. Pharmacol. Rev.
50: 21-34
[Abstract][Full Text]
Heesom, A. E, Millward, A., Demaine, A. G
(1998). Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene. J. Neurol. Neurosurg. Psychiatry
64: 213-216
[Abstract][Full Text]
Clark, C. M., Lee, D. A.
(1995). Prevention and Treatment of the Complications of Diabetes Mellitus. NEJM
332: 1210-1217
[Full Text]
Rendell, M., Bamisedun, O.
(1992). Skin Blood Flow and Current Perception in Pentoxifylline-Treated Diabetic Neuropathy. ANGIOLOGY
43: 843-851
[Abstract]
(1988). DIABETIC NEUROPATHY MAY BE SECONDARY TO BUILDUP OF ALCOHOL SUGARS. JWatch General
1988: 5-5
[Full Text]
Previous
